decibel db oto gene therapy

Decibel Therapeutics Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate DB-OTO

BOSTON, MASSACHUSSETTS — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, has announced the submission of Clinical Trial Applications (CTAs) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom and the Spanish Agency of Medicines and Medical…

Read More
decibel therapeutics db-oto

Decibel Therapeutics Announces Submission of IND Application for Lead Gene Therapy Candidate DB-OTO

BOSTON, MASSACHUSSETTS — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial in pediatric patients of DB-OTO,…

Read More
decibel therapeutics regeneron partnership extension

Decibel Therapeutics Announces Extension of Research Term with Regeneron for Development of Gene Therapy Hearing Loss Treatments

BOSTON, MASSACHUSSETTS –– Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Regeneron has extended the research term of its collaboration with the company to discover and develop gene therapies for hearing loss. The research term will be extended…

Read More
decibel therapeutics noise hearing loss genetics

Decibel Therapeutics Reports Q3 2021 Financial Results and Corporate Update

BOSTON, MASSACHUSSETTS — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. “Decibel continues to work towards bringing transformative treatments to patients with hearing and balance…

Read More
decibel therapeutics noise hearing loss genetics

Decibel Therapeutics Announces Publication of Foundational Study of Noise-Induced Inner Ear Damage

BOSTON, MASSACHUSSETTS — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that findings from a study of noise-related inner ear damage conducted in collaboration with the University of Maryland School of Medicine (UMSOM) and the Karolinska Institute (KI) have…

Read More
decibel therapeutics hearing loss treatment

Decibel Therapeutics Gene Therapy Hearing Loss Treatment, DB-OTO, Receives Orphan Drug and Rare Pediatric Disease Designations from FDA

BOSTON, MASSACHUSSETTS — Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation and Rare Pediatric Disease Designation for the company’s lead gene therapy product candidate, DB-OTO, for the…

Read More
decibel therapeutics ipo

Decibel Therapeutics Announces Pricing of Initial Public Offering; Raises $127M

BOSTON, MASSACHUSSETTS — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced the pricing of its initial public offering (IPO) of 7,062,000 shares of its common stock at a price to the public of $18.00 per share. All of the shares…

Read More
decibel therapeutics catalent

Decibel Therapeutics and Catalent Partner to Develop Gene Therapy for Treatment of Congenital Hearing Loss

SOMERSET, NEW JERSEY & BOSTON, MASSACHUSSETTS — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders, today announced they have signed…

Read More
amplify genetic testing program auditory neuropathy

Decibel Therapeutics and Invitae Announce Launch of Amplify™ Genetic Testing Program

BOSTON, MASSACHUSSETTS – Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing treatments to restore and improve hearing and balance, has announced a partnership with Invitae, a leading medical genetics company, to launch AmplifyTM, a no-charge genetic testing program to screen for the genetic cause of congenital hearing loss in children diagnosed with auditory neuropathy.…

Read More
decibel therapeutics ipo

Decibel Therapeutics Files for $75 Million IPO

BOSTON, MASSACHUSSETS — Decibel Therapeutics, a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, filed on Friday with the SEC to raise up to $75 million in an initial public offering (IPO). The news was first reported by IPO investment manager Renaissance Capital. The company is the latest…

Read More